May 2, 2023

BrightPath Biotherapeutics and Artisan Bio Announce
Research and Licensing Agreement to Accelerate
Development of BrightPath’s Novel Allogeneic iPSC Derived
Cell Therapy Platform across Multiple Indications
TOKYO and DENVER, May 2, 2023/ -- BrightPath Biotherapeutics Co., Ltd. (TYO: 4594), aclinical stage biotechnology company focused on the development of cell therapies derived
from invariant natural killer T (iNKT) cells, and Artisan Bio. Inc, a precision genome
engineering and drug discovery company, today announced they have signed a researchand licensing agreement to accelerate BrightPath's next-generation iNKT cell therapies toclinic.
BrightPath to receive non-exclusive rights to Artisan’s STAR-CRISPR editing platformto accelerate development of BrightPath’s invariant natural killer T (iNKT) cells

Artisan to receive an upfront payment and research milestones, plus license fees,development milestones, net sales milestones, and royalty on future products"This collaboration with Artisan provides BrightPath with the potential to create highly
engineered allogeneic iNKT cellular therapy programs for a range of indications, including
solid tumors," said Kenichi Nagai, BrightPath CEO. "Artisan's STAR-CRISPR system, and theirleading editing efficiencies in iPSC cells, will enable BrightPath's iNKT cell therapies to solve
the persistence and efficacy problems faced by first generation allogeneic CAR-T programs.""We are excited for the BrightPath collaboration and the development of highly engineered
iPS cells for cell therapy," said Ryan Gill, Artisan Bio CEO. "The BrightPath products will build
upon our leading STAR-CRISPR platform, our highly optimized guides for allogeneic andproprietary target genes, and our rigorous off-target safety profiling."
Under this agreement, BrightPath will pay Artisan an upfront payment and research
milestones for the development of CRISPR guides for the editing of BrightPath's iNKT cells.
BrightPath has the right to a commercial license for the STAR-CRISPR guides and nuclease
for a license fee plus development milestones, sales milestones, and a royalty on future
products.
About BrightPath:
BrightPath is a clinical stage biopharmaceutical company focused on the development ofnovel cancer immuno-therapies to transform cancer treatment for refractory or
progressive cancers that cannot be treated with conventional standard therapies.
BrightPath is actively involved in developing cell therapies currently in clinical trials,
immunomodulatory antibodies and new drugs targeted at cancer specific neoantigens.
For more information, visit www.brightpathbio.com/english/index.html

About Artisan:
Artisan Bio is a world-leader in CRISPR genome engineering technology and provides
drug developers with advanced genome engineering and drug discovery tools for theresearch and commercialization of cell and gene therapies, including companies such as
Takeda and Cabaletta Bio. Artisan's proprietary STAR-CRISPR gene editing platform
delivers leading editing efficiencies in multiple cell types including iPSC and T-cells, and isavailable through non-exclusive licenses. Artisan's SyionAI platform utilizes highthroughput CRISPR editing for novel drug discovery. For more information, visit
www.artisancells.com.
Forward-Looking Statements:
This news release contains forward-looking statements that are based on the current
expectations and beliefs of BrightPath. All statements, other than statements of historicalfact, are statements that could be deemed forward-looking statements. BrightPath
cautions that these forward-looking statements do not guarantee our future financial
results but involve risks and uncertainties that could cause actual results to differ
materially from those discussed in the forward-looking statements. These forwardlooking statements speak only as of the date of this press release and BrightPathassumes no duty to update forward-looking statements, except as may be required bylaw.
Investor and Media Contact:+81-3-5840-7697
irpr@brightpathbio.com
www.brightpathbio.com/english/index.html